

# 1Q24 RESULTS CALL PRESENTATION

1 MAY 2024

# **CONTENTS**

### **01** KEY DEVELOPMENTS

**02** MACROECONOMIC UPDATE | GEORGIA

**1Q24 PERFORMANCE OVERVIEW** 

**1Q24 PORTFOLIO RESULTS AND VALUATIONS OVERVIEW** 

**05** LIQUIDITY AND DIVIDEND INCOME OUTLOOK

06 WRAP-UP

**07** ANNEX



2

2

3

4

5

KEY DEVELOPMENTS IN 1Q24 Record NAV per share of GEL 90.04, up 8.6% q-o-q, supported by BoG's outstanding performance and share price growth

Strong performance of our private portfolio companies, aggregated quarterly revenue and EBITDA up 8.8% and 17.3% y-o-y, respectively

NCC ratio improved by 0.8 ppts q-o-q to 14.8% as at 31-Mar-24 (4.9 ppts improvement y-o-y), reflecting strong liquidity and continued growth in portfolio value

c.490,000 shares repurchased in 1Q24 (total bought back and cancelled since demerger now stands at 7.9 million shares (US\$ 87 million in value), representing c.16.5%<sup>1</sup> of the issued share capital at its peak)

GEL 13.8 million dividend income from the portfolio companies in 1Q24

Georgia Capital PLC | 1. Determined by taking into account the peak number of 47.9 million shares issued as of 31-Dec-20.

# CONTENTS

### KEY DEVELOPMENTS

MACROECONOMIC UPDATE | GEORGIA

1Q24 PERFORMANCE OVERVIEW

**1Q24 PORTFOLIO RESULTS AND VALUATIONS OVERVIEW** 

LIQUIDITY AND DIVIDEND INCOME OUTLOOK

06 WRAP-UP


ANNEX



### STRONG REAL GDP GROWTH IN 1Q24, WITH INFLATION BELOW TARGET




### GEORGIA'S ECONOMY CONTINUES TO EXPAND, WITH PRELIMINARY ECONOMIC GROWTH AT 7.8% Y-O-Y IN 1Q24



2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 1Q24\* \* Preliminary estimate


### NOMINAL GDP IN US DOLLARS SURGES TO US\$ 31 BILLION, NEARLY DOUBLING OVER A THREE-YEAR SPAN



#### \*\* IMF forecast

Georgia Capital PLC | Source: Geostat, NBG, IMF, WEO (April 2024)

### ANNUAL INFLATION BELOW THE 3% TARGET SINCE APRIL 2023, WITH MARCH 2024 INFLATION AT 0.5% Y-O-Y




GEORGIA'S MEDIUM-TERM GROWTH RATE PROJECTED TO BE ONE OF THE HIGHEST AMONG PEERS | IMF (APRIL 2024)




### **CURRENT ACCOUNT DEFICIT AT HISTORICALLY LOW LEVELS**



#### CAB NARROWED TO -4.3% OF GDP, SUPPORTED BY STRONG GROWTH IN THE SERVICES BALANCE




#### THE SHARE OF RUSSIA IN FX INFLOWS IS RETURNING TO PRE-WAR LEVELS



\*Quarterly Tourism data distribution between months since 3Q23 represents GCAP estimates.

#### FOREIGN CURRENCY INFLOWS HAVE MODERATED BUT REMAIN ABOVE PRE-WAR LEVELS



APPRECIATING SINCE MID-2021, GEL HAS STABILISED TO ABOVE PRE-PANDEMIC LEVELS AGAINST US\$



### STRONG LABOR MARKET SUPPORTING ECONOMIC ACTIVITY





2013 2014 2015 2016 2017 2018 2019 2020

UNEMPLOYMENT RATE AT HISTORICAL LOWS, DOWN TO 16.4% IN 2023 FROM 17.3% IN 2022


LABOR FORCE STRUCTURE

0.0%

2021

2022 2023

Employed Unemployed – Labor force – Labour force participation rate,%




2011 2012

0.0

2010


### **APPROPRIATE MACRO POLICY STANCE**






#### NET NBG INTERVENTIONS ON THE FX MARKET AND OFFICIAL RESERVE ASSETS

THE NBG CONTINUED TO EASE ITS TIGHTENED MONETARY POLICY STANCE WITH 125 BPS CUT IN 1Q24




GENERAL GOVERNMENT DEBT STRUCTURE FAVOURABLE, WITH 3.4% WEIGHTED AVERAGE INTEREST RATE




50% of external debt consists of fixed rate credits; Average weighted interest rate was 3.40%, while the remaining maturity stood at 9.0 years as of 31-Dec-23

#### **GENERAL GOVERNMENT DEBT BELOW PRE-WAR LEVELS**







STRONG GDP PERFORMACE

**BELOW-TARGET INFLATION** 

**ROBUST EXTERNAL BALANCE SHEET** 

**GEL/US\$ ABOVE PRE-PANDEMIC LEVELS** 

SOUND MACROECONOMIC FRAMEWORK

# CONTENTS

### **01** KEY DEVELOPMENTS

**02** MACROECONOMIC UPDATE | GEORGIA

**03** 1Q24 PERFORMANCE OVERVIEW

AGGREGATED PORTFOLIO RESULTS OVERVIEW NAV PER SHARE DEVELOPMENT OVERVIEW UPDATE ON DELEVERAGING

**1Q24 PORTFOLIO RESULTS AND VALUATIONS OVERVIEW** 

**05** LIQUIDITY AND DIVIDEND INCOME OUTLOOK

06 WRAP-UP


07 ANNEX



10


# AGGREGATED REVENUE DEVELOPMENT ACROSS PRIVATE PORTFOLIO





# AGGREGATED EBITDA DEVELOPMENT ACROSS PRIVATE PORTFOLIO







# AGGREGATED CASH BALANCE & NET OPERATING CASH FLOW DEVELOPMENT ACROSS PRIVATE PORTFOLIO



#### **TOTAL AGGREGATED NET OPERATING CASH FLOW** (GEL MILLION)



# **TOTAL AGGREGATED CASH BALANCE OF PRIVATE BUSINESSES** (GEL MILLION)



# **CONTENTS**

### **01** KEY DEVELOPMENTS

**02** MACROECONOMIC UPDATE | GEORGIA

**03** 1Q24 PERFORMANCE OVERVIEW

AGGREGATED PORTFOLIO RESULTS OVERVIEW <u>NAV PER SHARE DEVELOPMENT OVERVIEW</u> UPDATE ON DELEVERAGING

**1Q24 PORTFOLIO RESULTS AND VALUATIONS OVERVIEW** 

**05** LIQUIDITY AND DIVIDEND INCOME OUTLOOK

06 WRAP-UP

**07** ANNEX





# NAV PER SHARE (GEL) MOVEMENT IN 1Q24




### RECORD NAV PER SHARE OF GEL 90.04, UP 8.6% Q-O-Q IN 1Q24

 NAV per share (GEL) development in 1Q24 mainly reflects BoG's outstanding performance and share price growth.

 In GBP terms, the NAV per share growth in 1Q24 was 9.3%, driven by GEL's slight appreciation against GBP during the quarter.

	+ <b>9.6</b> %	-0.5%	+ <b>0.8%</b>	- <b>0.3</b> %	-1.0%	<u>+8.6%</u>
82.94						90.04
In GBP: <b>24.23</b>			+9.3%			In GBP: <b>26.48</b>
NAV per share 31-Dec-23	Listed & observable portfolio	Private portfolio	Buybacks	Operating expenses	Liquidity manag. /FX/Other	NAV per share 31-Mar-24

# **STRONG NAV PER SHARE GROWTH**





### STRONG NAV PER SHARE (GEL) GROWTH WITH 14.5% CAGR SINCE DEC-18


IN US\$ AND GBP TERMS, NAV PER SHARE CAGR STANDS AT 14.3% AND 14.4%, RESPECTIVELY

# SHARE BUYBACK AND CANCELLATION PROGRAMME



7.9 MILLION SHARES (US\$ 87 MILLION IN VALUE) REPURCHASED AND CANCELLED SINCE DEMERGER IN 2018, REPRESENTING 16.5%<sup>1</sup> OF THE ISSUED SHARE CAPITAL AT ITS PEAK

- 488,642 shares with the value of US\$ 6.7 million were repurchased under GCAP's US\$ 15 million share buyback and cancellation programme in 1Q24.
- In addition, 120,528 shares were repurchased for the management trust, representing the tax-related statutory buyback, where the average cost of unawarded shares is GBP 7.8 as of 31 March 2024.



# **CONTENTS**

### **01** KEY DEVELOPMENTS

**02** MACROECONOMIC UPDATE | GEORGIA

**03** 1Q24 PERFORMANCE OVERVIEW

AGGREGATED PORTFOLIO RESULTS OVERVIEW NAV PER SHARE DEVELOPMENT OVERVIEW UPDATE ON DELEVERAGING

**04** 1Q24 PORTFOLIO RESULTS AND VALUATIONS OVERVIEW

**05** LIQUIDITY AND DIVIDEND INCOME OUTLOOK

06 WRAP-UP

**07** ANNEX



18

# **NET CAPITAL COMMITMENT (NCC) OVERVIEW**



### NCC RATIO IMPROVED BY 0.8 PPTS Q-O-Q AND 4.9 PPTS Y-O-Y TO 14.8% AS AT 31-MAR-24

• The improvement in the NCC ratio in 1Q24 was mainly driven by the 7.9% growth in total portfolio value.

US\$ Million	31-Mar-23	Change (y-o-y)	31-Dec-23	Change (q-o-q)	31-Mar-24
Cash and liquid funds	134.5	-80.9%	40.1	-35.9%	25.7
Loans issued	13.9	-74.5%	3.4	3.2%	3.5
Gross debt	(299.2)	-49.6%	(153.9)	-2.1%	(150.7)
Net debt (1)	(150.8)	-19.5%	(110.4)	10.0%	(121.4)
Guarantees issued (2)	(1.6)	NMF	-	NMF	-
Net debt and guarantees issued (3)=(1)+(2)	(152.5)	-20.4%	(110.4)	10.0%	(121.4)
Planned investments (4)	(48.7)	-4.4%	(46.5)	NMF	(46.5)
of which, planned investments in Renewable Energy	(30.1)	-3.9%	(28.9)	NMF	(28.9)
of which, planned investments in Education	(18.6)	-5.2%	(17.7)	NMF	(17.7)
Announced Buybacks (5)	-	NMF	(6.7)	NMF	-
Contingency/liquidity buffer (6)	(50.0)	NMF	(50.0)	NMF	(50.0)
Total planned investments, announced buybacks and contingency/liquidity buffer (7)=(4)+(5)+(6)	(98.7)	-2.2%	(103.3)	-6.5%	(96.5)
Net capital commitment (3)+(7)	(251.2)	-13.2%	(213.6)	2.0%	(218.0)
Portfolio value	1,276.2	15.4%	1,365.3	<b>7.9</b> %	1,473.2
NCC ratio	19.7%	-4.9 ppts	15.6%	-0.8 ppts	14.8%


# NCC RATIO DEVELOPMENT OVERVIEW



NCC REPRESENTS AN AGGREGATED VIEW OF ALL CONFIRMED, AGREED AND EXPECTED CAPITAL OUTFLOWS AT THE GCAP HOLDCO LEVEL

We are targeting to reduce the balance of "net debt and guarantees issued" close to zero over the medium-term

#### NCC AND NCC RATIO DEVELOPMENT OVERVIEW<sup>1</sup>




# **FREE CASH FLOW DEVELOPMENT**



SIGNIFICANT INCREASE IN FREE CASH FLOW, REFLECTING ROBUST DIVIDEND INFLOWS, WELL-MANAGED OPERATING EXPENSES, AND REDUCED INTEREST EXPENSE IN LINE WITH OUR DELEVERAGING PROGRESS

Free cash flow is determined by subtracting interest and operating expenses from dividend and interest income.



- 1. The 2023 free cash flow excludes US\$ 22 million one-off dividends and US\$ 17 million buyback dividends from the participation in BoG's FY23 buybacks.
- 2. The 2024 free cash flow excludes buyback dividends.

# CONTENTS

KEY DEVELOPMENTS

MACROECONOMIC UPDATE | GEORGIA

1Q24 PERFORMANCE OVERVIEW

1Q24 PORTFOLIO RESULTS AND VALUATIONS OVERVIEW

LIQUIDITY AND DIVIDEND INCOME OUTLOOK

06 WRAP-UP


ANNEX






# **PORTFOLIO VALUE AS OF 31-MAR-24**





#### % SHARE IN TOTAL PORTFOLIO VALUE:



Georgia Capital PLC | 1. The independent valuations of the large and investment portfolio companies are performed on a semi-annual basis. In 1Q24, our private large and investment portfolio companies were valued

internally by incorporating 1Q24 results, in line with IPEV guidelines and methodology deployed in 2023 by a third-party independent valuation firm.

2. The valuation of Water Utility in 1Q24 reflects the application of the put option valuation to GCAP's 20% holding in the business.

LTM EV/EBITDA multiples for Retail (Pharmacy), Hospitals and Clinics & Diagnostics are presented including IFRS 16 as of 31-Mar-24.
 Blended multiple for the operational assets of Renewable Energy is 12.4x, while other pipeline projects are stated at cost.

5. The forward-looking implied valuation multiple is estimated at 11.0x for the 2024-2025 academic year.


# **PORTFOLIO VALUE DEVELOPMENT IN 1Q24**



### PORTFOLIO VALUE UP 8.1% Q-O-Q TO GEL 4.0 BILLION IN 1Q24

#### PRIVATE PORTFOLIO VALUE CREATION IN 1Q24

PRIVATE PORTFOLIO VALUE CREATIC		
GEL million		
Education	13.3	
Clinics & Diagnostics	9.7	
Other businesses	6.2	
Insurance (P&C & Medical)	4.3	
Renewable Energy	(0.7)	
Retail (Pharmacy)	(20.0)	
Hospitals	(30.4)	
Total	(17.6)	




# RETAIL (PHARMACY) BUSINESS OPERATING PERFORMANCE OVERVIEW






#### **KEY DRIVERS**

- A y-o-y increase in revenues reflects:
  - An 8.7% y-o-y increase in retail revenues, driven by significant recent expansion of the retail chain and the increased demand for seasonal medicines due to the increased flu activity in 1Q24.
  - A 15.0% y-o-y decrease in wholesale revenues, mainly driven by time discrepancies in State tender occurrences.
- Gross profit and gross profit margin up 5.0% and 0.4 ppts y-o-y, respectively, in 1Q24.
- Operating expenses were up 21.4% y-o-y in 1Q24, due to increased rent and salary costs related to the expansion and the launch of a new warehouse at the end of 2023.
- The business added 53 pharmacies and franchise stores over the last 12 months.



#### **KEY OPERATING HIGHLIGHTS**



5

# **RETAIL (PHARMACY) BUSINESS** VALUATION OVERVIEW





hange q-o-q		-2.1%	-0.8%	0.0%	-2.8%
1,044	(22)	1,022			
			(320)	(8)	694
nterprise value	Net change	Enterprise value	Net debt inc.	Minority	Equity value
31-Dec-23	in EV	31-Mar-24	financial leases	interest	31-Mar

#### VALUATION HIGHLIGHTS<sup>1</sup>

GEL million, unless noted otherwise	31-Mar-24	31-Dec-23	Change
Enterprise value	1,021.6	1,043.8	(22.2)
LTM EBITDA	105.3	107.6	(2.3)
Implied EV/EBITDA multiple	9.7x	9.7x	-
Net debt inc. lease liabilities	(319.6)	(322.2)	2.6
Equity value of GCAP's share	694.4	714.0	(19.6)

#### **IMPLIED LTM EV/EBITDA DEVELOPMENT**







Georgia Capital PLC | 1. The independent valuations of the large and investment portfolio companies are performed on a semi-annual basis. In 1Q24, our private large and investment portfolio companies were valued internally by incorporating 1Q24 results, in line with IPEV guidelines and methodology deployed in 2023 by a third-party independent valuation firm. 2. Figures take into account the application of the minority buyout agreement.


# **HOSPITALS BUSINESS OPERATING PERFORMANCE OVERVIEW**





#### **KEY DRIVERS**

- The y-o-y increase in the 1Q24 revenue reflects the net impact of:
  - Increase in revenues from Iashvili Hospital in 1Q24, which was closed in 1Q23 due to mandatory regulatoryrelated renovation works.
  - Decrease in the share of revenues from the State in 0 large and specialty hospitals (down from 58.1% in 1Q23 to 54.8% in 1Q24), partially offsetting the impact of the facility regulation rules enforced in September 2023.
  - The absence of revenues from Batumi Hospital (one of 0 the regional hospitals), which was divested in 4Q23.
- Adjusted for the sale of Batumi Hospital, the revenue was up by 7.6%<sup>1</sup> and EBITDA was down by 8.2% y-o-y in 1Q24.
- Operating expenses were up by 10.6% y-o-y in 1Q24, resulting from an increase in the impairment of receivables, in line with the increased share of out-ofpocket revenues.




#### **KEY OPERATING HIGHLIGHTS**

**GEL MILLION** 

Bed occupancy rate		1Q23	VS.	■ 1Q24		<u>Change y-o-y</u>
Large and specialty hospitals	54.2%				69.8%	+15.6 ppts
Regional hospitals	53.4%				75.0%	+21.6 ppts
Number of admissions	-					
Large and specialty hospitals	139.7				176.9	+26.6%
Regional and community hospitals	221.3				237.4	+7.3%


# HOSPITALS BUSINESS VALUATION OVERVIEW




#### VALUATION HIGHLIGHTS<sup>1</sup>

GEL million, unless noted otherwise	31-Mar-24	31-Dec-23	Change
Enterprise value	606.9	618.9	(12.0)
LTM EBITDA	43.9	44.8	(0.9)
Implied EV/EBITDA multiple	13.8x	13.8x	-
Net debt incl. lease liabilities	(259.2)	(241.1)	(18.1)
Equity value of GCAP's share	314.3	344.4	(30.1)

#### **IMPLIED LTM EV/EBITDA DEVELOPMENT**









Georgia Capital PLC | 1. The independent valuations of the large and investment portfolio companies are performed on a semi-annual basis. In 1Q24, our private large and investment portfolio companies were valued internally by incorporating 1Q24 results, in line with IPEV guidelines and methodology deployed in 2023 by a third-party independent valuation firm.

# INSURANCE BUSINESS OPERATING PERFORMANCE OVERVIEW







#### **KEY DRIVERS**

- The increase in insurance revenue is mainly driven by the growth in the motor, credit life and medical insurance lines.
- The combined ratio of P&C Insurance was up 4.3 ppts y-o-y 1Q24, resulting from the foreign exchange rate movements.
- The combined ratio of Medical Insurance increased by 1.4 ppts y-o-y in 1Q24, mainly driven by the 0.9 ppts y-o-y increase in the expense ratio resulting from the increased salaries and other employee benefits in line with the business growth.

In April 2024, the business completed the previously announced acquisition of GEL 87 million portfolio of insurance contracts together with the strong brand name "Ardi" for a total cash outflow of GEL 26.4 million, doubling our presence in the medical insurance business.




#### PRE-TAX PROFIT DEVELOPMENT



#### **KEY OPERATING HIGHLIGHTS**


P&C Insurance		
	Gross premium written (MGEL)	30.1
	Combined ratio	82.8%
	Number of policies written	72,156
Medical Insurance		
	Gross premium written (MGEL)	47.5
	Combined ratio	95.8%
	Number of individuals insured	170,222



# INSURANCE BUSINESS VALUATION OVERVIEW

### VALUE DEVELOPMENT OVERVIEW | 1Q24


(GEL MILLION)




#### VALUATION HIGHLIGHTS<sup>1</sup>

GEL million, unless noted otherwise	31-Mar-24	31-Dec-23	Change
LTM pre-tax profit	30.4	30.4	-
Implied P/E multiple	12.4x	12.4x	-
Equity value	377.7	377.9	(0.2)
LTM ROAE <sup>2</sup> – P&C Insurance	25.9%	24.4%	1.5 ppts
LTM ROAE – Medical Insurance	16.0%	17.2%	(1.2) ppts

#### IMPLIED LTM P/E MULTIPLE DEVELOPMENT



#### NET DEBT TO EBITDA



Georgia Capital PLC | 1. The independent valuations of the large and investment portfolio companies are performed on a semi-annual basis. In 1Q24, our private large and investment portfolio companies were valued internally by incorporating 1Q24 results, in line with IPEV guidelines and methodology deployed in 2023 by a third-party independent valuation firm. 2. Calculated based on average equity, adjusted for preferred shares.




# RENEWABLE ENERGY BUSINESS OPERATING PERFORMANCE OVERVIEW





#### **KEY DRIVERS**


- A y-o-y increase in the 1Q24 revenue and EBITDA reflects the increase in electricity generation, driven by the resumption of operations of two power-generating units of Hydrolea HPPs, which were taken offline during the November 2022 - June 2023 period.
- In 1Q24, the business repurchased and cancelled US\$ 5.1 million of its outstanding bond, resulting in a decrease in the gross debt balance to US\$ 74.9 million.



#### **KEY OPERATING HIGHLIGHTS**




# RENEWABLE ENERGY BUSINESS VALUATION OVERVIEW




#### VALUATION HIGHLIGHTS<sup>1</sup>

US\$ million, unless noted otherwise	31-Mar-24	31-Dec-23	Change
Enterprise value	170.4	169.6	0.8
EBITDA	12.1	12.0	0.1
Implied EV/EBITDA multiple <sup>2</sup>	12.4x	12.6x	(0.2)x
Investments at cost (EV) <sup>3</sup>	20.3	19.5	0.8
Net debt	(71.6)	(70.5)	(1.1)
Equity value	98.8	99.1	(0.3)

EQUITY FAIR VALUE COMPOSITION AT 31-MAR-24 (US\$ MILLION)



#### **NET DEBT TO EBITDA<sup>4</sup>**



**Georgia Capital PLC** [ 1. The independent valuations of the large and investment portfolio companies are performed on a semi-annual basis. In 1Q24, our private large and investment portfolio companies were valued internally by incorporating 1Q24 results, in line with IPEV guidelines and methodology deployed in 2023 by a third-party independent valuation firm. 2. Implied EV/EBITDA is calculated based on normalised LTM EBITDA. 3. Investments at cost include the pipeline projects. 4. Ratio is calculated in US\$ terms.

GEORGIA

# EDUCATION BUSINESS OPERATING PERFORMANCE OVERVIEW






#### **KEY DRIVERS**

- A y-o-y increase in the 1Q24 revenue was driven by:
- The organic growth through strong intakes and a ramp-up of the utilisation; and
- expansion of the business through the launch and acquisition of two new campuses in 2023.
- On a constant currency basis, the y-o-y revenue growth in 1Q24 amounted to 39.9%.
- Operating expenses were up by 47.1% y-o-y in 1Q24, mainly reflecting increased salary, catering and utility expenses, in line with the expansion of the business.
- EBITDA was up by 10.0% y-o-y in 1Q24 (up 27.6% on a constant currency basis).
- The total number of learners increased by 1,373 learners y-o-y to 5,885 learners at 31-Mar-2024.



#### **KEY OPERATING HIGHLIGHTS**



# EDUCATION BUSINESS VALUATION OVERVIEW

#### VALUE DEVELOPMENT OVERVIEW | 1Q24


### (GEL MILLION)

Change q-o	p-q	+5.1%	+2.0%	-25.0%	+5.6%	+7.1%
229	12	241	31	(12)		202
		s.		(12)	(57)	203
Enterprise value 31-Dec-23	Net change in EV	Enterprise value 31-Mar-24	Investment at cost	Net debt	Minority interest <sup>2</sup>	Equity value 31-Mar-24


#### VALUATION HIGHLIGHTS<sup>1</sup>

GEL million, unless noted otherwise	31-Mar-24	31-Dec-23	Change
Enterprise value	240.5	228.8	11.7
LTM EBITDA <sup>3</sup>	14.9	13.7	1.2
Implied EV/EBITDA multiple	16.2x	16.7x	(0.5)x
Net debt	(12.4)	(16.5)	4.1
Investments at cost	31.1	30.5	0.6
Total equity value of GCAP's share	202.6	189.2	13.4

#### LTM EV/EBITDA DEVELOPMENT<sup>4</sup>



#### NET DEBT TO EBITDA



**Georgia Capital PLC** [ 1. The independent valuations of the large and investment portfolio companies are performed on a semi-annual basis. In 1Q24, our private large and investment portfolio companies were valued internally by incorporating 1Q24 results, in line with IPEV guidelines and methodology deployed in 2023 by a third-party independent valuation firm. 2. GCAP has different ownership stakes across schools (70-90%). 3. The LTM EBITDAs used in the valuation assessment of the education business incorporate the functional currency adjustment at certain schools. The LTM EBITDA calculations do not factor the performance of a recently launched schools, which are added to the equity value of the business at cost. 4. The forward-looking implied valuation multiple is estimated at 11.0x for the 2024-2025 academic year.




# CLINICS & DIAGNOSTICS BUSINESS OPERATING PERFORMANCE OVERVIEW






#### **KEY DRIVERS**


- A y-o-y growth in the 1Q24 revenue and EBITDA reflects:
  - the increased demand for high revenue-generating services driven by the business's proactive approach to customer acquisition and service enhancements,
  - the expansion of the business through the launch of two new ambulatory centres in 2H23.
- Gross profit and gross profit margin up 38.0% and 5.4 ppts y-o-y, respectively, in 1Q24.
- Operating expenses were up by 17.9% y-o-y in 1Q24, in line with the expansion.




#### **KEY OPERATING HIGHLIGHTS**



#### **EBITDA<sup>2</sup> DEVELOPMENT**





# CLINICS & DIAGNOSTICS BUSINESS VALUATION OVERVIEW

#### VALUE DEVELOPMENT OVERVIEW | 1Q24 (GEL MILLION)


Change q-o-q		+3.6%	-6.7%	+10.1%	+8.8%
172	6	178			
			(55)	(3)	121
Enterprise value 31-Dec-23	Net change in EV	Enterprise value 31-Mar-24	Net debt inc. financial leases	Minority interest	Equity value 31-Mar-24

#### VALUATION HIGHLIGHTS<sup>1</sup>

GEL million, unless noted otherwise	31-Mar-24	31-Dec-23	Change	
Enterprise value	177.9	171.8	6.1	
LTM EBITDA	16.8	14.7	2.1	
Implied EV/EBITDA multiple	10.6x	11.7x	(1.1)x	
Net debt incl. lease liabilities	(54.6)	(58.5)	3.9	
Equity value of GCAP's share	120.6	110.8	9.8	

#### IMPLIED LTM EV/EBITDA DEVELOPMENT





Georgia Capital PLC | 1. The independent valuations of the large and investment portfolio companies are performed on a semi-annual basis. In 1Q24, our private large and investment portfolio companies were valued internally by incorporating 1Q24 results, in line with IPEV guidelines and methodology deployed in 2023 by a third-party independent valuation firm.

GEORGIA

# CONTENTS

**01** KEY DEVELOPMENTS

**02** MACROECONOMIC UPDATE | GEORGIA

**03** 1Q24 PERFORMANCE OVERVIEW

**1Q24 PORTFOLIO RESULTS AND VALUATIONS OVERVIEW** 

**05** LIQUIDITY AND DIVIDEND INCOME OUTLOOK

06 WRAP-UP


07 ANNEX





# LIQUIDITY OUTLOOK

#### LIQUIDITY DEVELOPMENT OVERVIEW (US\$ MILLION)






\*LIQUIDITY DOWN BY 35.9% Q-O-Q IN 1Q24, REFLECTING SHARE BUYBACKS DURING THE QUARTER AND COUPON PAYMENT ON US\$ 150 MILLION SUSTAINABILITY-LINKED BOND

# **DIVIDEND INCOME OUTLOOK**

#### **RECURRING CASH DIVIDEND INCOME FROM PORTFOLIO COMPANIES**



### \* IN ADDITION TO THE RECURRING DIVIDENDS, GCAP RECEIVED A ONE-OFF NON-RECURRING INFLOW OF GEL 56.1 MILLION IN 2023:

- 1) GEL 29.4 million from the participation in BOG's 2022 share buybacks;
- 2) One-off additional dividend of GEL 26.7 from the retail (pharmacy) business, following the minority buyout.



#### **GEL 13.8 MILLION DIVIDEND INCOME IN 1Q24**

DIVIDEND INCOME	(GEL million)
P&C Insurance	4.8
Beverages (beer business)	4.6
BOG (buyback dividend)	4.3
TOTAL	13.8

#### SOLID DIVIDEND INCOME OUTLOOK IN 2024

**180-190** GEL MILLION

# CONTENTS

KEY DEVELOPMENTS

MACROECONOMIC UPDATE | GEORGIA

1Q24 PERFORMANCE OVERVIEW

**1Q24 PORTFOLIO RESULTS AND VALUATIONS OVERVIEW** 

LIQUIDITY AND DIVIDEND INCOME OUTLOOK

06 WRAP-UP

**ANNEX** 



# SOLID PERFORMANCE ACROSS OUR PORTFOLIO



#### **PERFORMANCE HIGHLIGHTS**

✓	Record NAV per share of GEL 90.04, up 8.6% q-o-q, supported by BoG's outstanding performance and share price growth
$\checkmark$	Strong performance of our private portfolio companies, aggregated quarterly revenue and EBITDA up 8.8% and 17.3% y-o-y, respectively
✓	NCC ratio improved by 0.8 ppts q-o-q to 14.8% as at 31-Mar-24 (4.9 ppts improvement y-o-y), reflecting strong liquidity and continued growth in portfolio value
✓	c.490,000 shares repurchased in 1Q24 (total bought back and cancelled since demerger now stands at 7.9 million shares (US\$ 87 million in value), representing c.16.5% of the issued share capital at its peak)
$\checkmark$	GEL 13.8 million dividend income from the portfolio companies in 1Q24

#### OUTLOOK

€	Significant value creation potential across our portfolio companies, supported by the recent expansion in the insurance business
€	Substantial progress on deleveraging
€	Strong economic growth outlook

# **CONTENTS**

KEY DEVELOPMENTS

MACROECONOMIC UPDATE | GEORGIA

1Q24 PERFORMANCE OVERVIEW

**1Q24 PORTFOLIO RESULTS AND VALUATIONS OVERVIEW** 

LIQUIDITY AND DIVIDEND INCOME OUTLOOK

06 WRAP-UP

ANNEX



# **DELEVERAGING ACROSS OUR PRIVATE PORTFOLIO**



AGGREGATED LEVERAGE ACROSS OUR PRIVATE LARGE AND INVESTMENT STAGE PORTFOLIO COMPANIES AT 3.2x AS OF 31-MAR-24

ADJU	STED NET DEBT/EBITDA	31-DEC-23	CHANGE	31-MAR-24	TARGET (OVER THE CYCLE)
LARGE PORTFOLIO COMPANIES					
•	Retail (pharmacy) <sup>1</sup>	2.2x	+0.1x	2.3x	Up to 1.5x
•	Hospitals	5.3x <sup>2</sup>	+0.5x	5.8x <sup>2</sup>	Up to 2.5x
•	Insurance (P&C and Medical)	No leverage	NMF	No leverage	No leverage
INVESTMENT STAGE PORTFOLIO COMPANIES					
G	Renewable Energy <sup>3</sup>	6.8x	-0.4x	6.4x	Up to 6.0x
	Education	1.4x	-0.2x	1.2x	Up to 2.5x
8	Clinics and Diagnostics	3.6x <sup>4</sup>	-0.8x	2.8x <sup>4</sup>	Up to 2.5x

**Georgia Capital PLC |** General note: Figures for Hospitals, Retail (Pharmacy), Clinics and Diagnostics are given excluding IFRS 16 effects; Net debt/EBITDA is adjusted for capital commitments. 1. Includes the application of the minority buyout agreement. 2. EBITDA excludes the performance of the divested regional hospital, while net debt takes into account the cash proceeds from the transaction. 3. Renewable energy ratio is calculated in US\$. 4. LTM EBITDA excludes the gain of GEL 2.9 million from the sale of one of the polyclinics buildings in 3Q23.

# PRIVATE PORTFOLIO COMPANIES' DEBT MATURITY PROFILE



(GEL MILLION)	2024	2025	2026	2027-2036	Total
Large portfolio companies	220.6	87.4	47.3	45.3	400.6
Retail (pharmacy) <sup>1</sup>	117.0	30.0	27.0	18.6	192.6
Hospitals	103.6	57.4	20.3	26.7	208.0
Investment stage portfolio companies	19.4	14.4	7.4	215.7	256.9
Renewable Energy	-	0.6	-	201.9	202.5
Education	3.2	2.4	2.6	12.0	20.2
Clinics and Diagnostics	16.2	11.4	4.8	1.8	34.2
Other businesses <sup>2</sup>	171.1	34.9	49.1	48.6	303.7
Total	411.1	136.7	103.8	309.6	961.2

1. Includes GEL c.40 million debt for financing the minority shareholder buyout in FY23.

2. Gross debt of other businesses includes a 2-year US\$ 35 million bonds issued by the housing development business in Oct-22.



# **VALUATION PEER GROUP**



RETAIL (PHARMACY)

- NEUCA S.A. | Poland
- Sopharma Trading AD | Bulgaria
- S.C. Ropharma S.A. | Romania
- SALUS, Ljubljana, d. d. | Slovenia
- Great Tree Pharmacy Co., Ltd. | Taiwan
- Dis-Chem Pharmacies Limited | South Africa
- Clicks Group Limited | South Africa



- Medicover AB | Sweden
- EMC Instytut Medyczny SAEMC SA | Poland
- Med Life S.A. | Romania
- Netcare Limited | South Africa
- MLP Saglik Hizmetleri A.S. | Turkey
- Life Healthcare Group Holdings Limited | South Africa





P&C INSURANCE

- Dhipaya Insurance | Thailand
- Zavarovalnica Triglav | Slovenia
- Pozavarovalnica Sava | Slovenia
- Aksigorta | Turkey
- Anadolu Sigorta | Turkey
- Bao Minh Insurance | Vietnam
- Turkiye Sigorta | Turkey



- Powszechny Zaklad Ubezpieczen SA | Poland
- Allianz SE | Germany
- UNIQA Insurance Group AG | Austria
- Ageas SA/NV | Belgium





- SISB Public Company Limited | Thailand
- Curro Holdings Limited | South Africa
- Overseas Education Limited | Singapore
- Cairo For Investment & Real Estate Development S.A.E | Egypt
- Cogna Educação S.A. | Brazil
- Colegios Peruanos S.A. | Peru
- ADvTECH Limited | South Africa



CLINICS AND DIAGNOSTICS

- EMC Instytut Medyczny SA | Poland
- Med Life S.A. | Romania
- Medicover AB | Sweden
- Fleury S.A. | Brazil



- BCPG Public Company Limited | Thailand
- ERG S.p.A | Italy
- Polenergia S.A. | Poland
- Terna Energy Societe
  Anonyme | Greece

# FORWARD LOOKING STATEMENTS



This presentation contains forward-looking statements, including, but not limited to, statements concerning expectations, projections, objectives, targets, goals, strategies, future events, future revenues or performance, capital expenditures, financing needs, plans or intentions relating to acquisitions, competitive strengths and weaknesses, plans or goals relating to financial position and future operations and development. Although Georgia Capital PLC believes that the expectations and opinions reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations and opinions will prove to have been correct. By their nature, these forward-looking statements are subject to a number of known and unknown risks, uncertainties and contingencies, and actual results and events could differ materially from those currently being anticipated as reflected in such statements. Important factors that could cause actual results to differ materially from those expressed or implied in forward-looking statements, eretain of which are beyond our control, include, among other things: regional instability; regional instability; currency fluctuations and risk, including depreciation of the Georgian Lari, and macroeconomic risk, regulatory risk across a wide range of industries; investment risk; liquidity risk; portfolio company strategic and execution risks; and other key factors that could adversely affect our business and financial performance, including those which are contained elsewhere in this presentation constitutes, or shall be taken to constitute, an invitation or inducement to invest in Georgia Capital PLC or any other entity and must not be relied upon in any way in connection with any investment decision. Georgia Capital PLC and other entities undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent legally required. Nothing in this presentation should be construed as a profit fore